Financials Medica S.p.A.

Equities

MDC

IT0005460149

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-05-10 am EDT			5-day change	1st Jan Change
26.8 ^EUR	0.00%		+1.52%	+72.90%

Apr. 29	Donaldson Agrees to Acquire 49% Stake in Medica	MT
Apr. 26	Response Plus Unit Closes Prometheus Medical Acquisition	MT

Valuation

Fiscal Period: December	2021	2022	2023	2024	2025
Capitalization ¹	170	110.2	113.2	113.2	-
Enterprise Value (EV) ¹	159.2	114.6	65.46	119.1	108.4
P/E ratio	34.1 x	25.3 x	56.4 x	16.6 x	12.1 x
Yield	-	-	-	-	-
Capitalization / Revenue	3.88 x	2.17 x	0.82 x	1.22 x	1.12 x
EV / Revenue	3.63 x	2.25 x	0.82 x	1.28 x	1.07 x
EV / EBITDA	16.1 x	10.3 x	5.59 x	6.69 x	5.23 x
EV / FCF	-35.7 x	-7.37 x	-20.3 x	15.4 x	10.1 x
FCF Yield	-2.8%	-13.6%	-4.94%	6.51%	9.87%
Price to Book	3.78 x	2.24 x	2.06 x	1.88 x	1.63 x
Nbr of stocks (in thousands)	4,223	4,223	4,223	4,223	-
Reference price ²	40.25	26.10	26.80	26.80	26.80
Announcement Date	3/30/22	3/30/23	3/25/24	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Net sales ¹	44.06	43.8	50.86	79.98	93.11	101.5
EBITDA ¹	-	9.897	11.17	11.72	17.79	20.74
EBIT ¹	-	5.824	5.264	4.56	9.625	12.54
Operating Margin	-	13.3%	10.35%	5.7%	10.34%	12.35%
Earnings before Tax (EBT) ¹	-	5.617	4.811	3.41	8.58	11.75
Net income ¹	3.772	4.973	4.35	2.967	6.825	9.335
Net margin	8.56%	11.35%	8.55%	3.71%	7.33%	9.2%
EPS ²	-	1.180	1.030	0.4750	1.615	2.210
Free Cash Flow ¹	-	-4.459	-15.55	-6.1	7.75	10.7
FCF margin	-	-10.18%	-30.58%	-7.95%	8.32%	10.54%
FCF Conversion (EBITDA)	-	-	-	-	43.56%	51.58%
FCF Conversion (Net income)	-	-	-	-	113.55%	114.62%
Dividend per Share	-	-	-	-	-	-
Announcement Date	12/27/21	3/30/22	3/30/23	3/25/24	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2022 S1	2022 S2	2023 S2
Net sales	20.42	30.44	-
EBITDA ¹	-	7.415	8
EBIT ¹	-	3.568	4.354
Operating Margin	-	11.72%	-
Earnings before Tax (EBT) ¹	-	3.183	3.794
Net income ¹	1.27	3.08	2.784
Net margin	6.22%	10.12%	-
EPS	-	-	-
Dividend per Share	-	-	-
Announcement Date	9/28/22	3/30/23	3/25/24

¹EUR in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Net Debt ¹	-	-	4.34	10.4	5.92	-
Net Cash position ¹	-	10.8	-	-	-	4.79
Leverage (Debt/EBITDA)	-	-	0.3883 x	0.9216 x	0.3325 x	-
Free Cash Flow ¹	-	-4.46	-15.6	-6.1	7.75	10.7
ROE (net income / shareholders' equity)	-	14.9%	8.94%	-	11.9%	14.1%
ROA (Net income/ Total Assets)	-	8.55%	5.41%	3.8%	10.9%	13.1%
Assets ¹	-	58.16	80.36	52.63	62.61	71.26
Book Value Per Share ²	-	10.70	11.70	13.00	14.20	16.50
Cash Flow per Share	-	1.010	-	-	4.460	4.190
Capex	-	8.73	6.93	-	7	4.3
Capex / Sales	-	19.94%	13.63%	-	7.52%	4.24%
Announcement Date	12/27/21	3/30/22	3/30/23	3/25/24	-	-

¹EUR in Million²EUR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Medica S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.8 EUR

Average target price

31.4 EUR

Spread / Average Target

+17.16%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDICA S.P.A.	+72.90%	122M
MODERNA, INC.	+17.96%	44.96B
LONZA GROUP AG	+48.77%	41.85B
IQVIA HOLDINGS INC.	+1.17%	42.65B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research